Document Detail


Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation.
MedLine Citation:
PMID:  6144975     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Prevention of aortocoronary bypass occlusion by aspirin (ASA, 1 X 100 mg per day) was studied in a prospective double-blind trial of 83 patients. 60 (72%) were randomly allocated to ASA or placebo starting 24 h after operation. 90% of grafts in the ASA group and 68% in the placebo group were patent at four months. At least one anastomosis was occluded in 62% of the patients on placebo and in 27% of those on aspirin. Ventricular arrhythmias increased after surgery in more patients on placebo (12/18) than in patients on ASA (5/17). Platelet thromboxane formation on collagen tested before operation was significantly higher in patients in whom bypass occlusion developed (occlusion: 40 +/- 19, no occlusion: 25 +/- 13 ng/ml). A 100 mg dose of ASA per day effectively blocked platelet thromboxane formation and thromboxane-supported aggregation on collagen and was safe in the postoperative phase. No side effects were reported throughout the trial. The reduced toxicity with full efficacy favours a low and infrequent dosage of aspirin.
Authors:
R L Lorenz; C V Schacky; M Weber; W Meister; J Kotzur; B Reichardt; K Theisen; P C Weber
Related Documents :
14636765 - Subeschar clysis in deep burns.
8583435 - The function of free jejunal autografts in the pharyngo-oesophageal segment.
23194375 - Treatment of lamivudine-resistant chronic hepatitis b infection: a multicenter retrospe...
8040165 - Local thrombolysis for occluded arterial grafts: is the yield worth the effort?
18043315 - Importance of baseline prognostic factors with increasing time since initiation of high...
20096225 - Impact of mucosal eosinophilia and nasal polyposis on quality-of-life outcomes after si...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1984 Jun 
Date Detail:
Created Date:  1984-07-16     Completed Date:  1984-07-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1261-4     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aspirin / administration & dosage,  pharmacology*
Blood Platelets / metabolism
Clinical Trials as Topic
Coronary Artery Bypass*
Double-Blind Method
Female
Graft Survival
Humans
Male
Middle Aged
Platelet Aggregation / drug effects*
Prospective Studies
Random Allocation
Thromboxanes / biosynthesis*
Chemical
Reg. No./Substance:
0/Thromboxanes; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopaus...
Next Document:  Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial in...